Cargando…

The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with variable clinical outcome, accounting for at least 25-30 % of adult non-Hodgkin lymphomas. Approximately one third of DLBCL patients are not cured by the currently used treatment regimen, R-CHOP. Hence, new treatment str...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reinholdt, Linn, Laursen, Maria Bach, Schmitz, Alexander, Bødker, Julie Støve, Jakobsen, Lasse Hjort, Bøgsted, Martin, Johnsen, Hans Erik, Dybkær, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908729/ https://www.ncbi.nlm.nih.gov/pubmed/27307990 http://dx.doi.org/10.1186/s40364-016-0067-2

Ejemplares similares

High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients
por: Laursen, Maria Bach, et al.
Publicado: (2019)

Molecular classification of tissue from a transformed non-Hogkin’s lymphoma case with unexpected long-time remission
por: Bødker, Julie Støve, et al.
Publicado: (2017)

Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition
por: Falgreen, Steffen, et al.
Publicado: (2014)

MicroRNAs in B-cells: from normal differentiation to treatment of malignancies
por: Marques, Sara Correia, et al.
Publicado: (2014)

Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact
por: Schönherz, Anna A., et al.
Publicado: (2020)

Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow – A proof of concept study
por: Nørgaard, Caroline Holm, et al.
Publicado: (2018)

Long Noncoding RNA Expression during Human B-Cell Development
por: Petri, Andreas, et al.
Publicado: (2015)

hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine
por: Falgreen, Steffen, et al.
Publicado: (2016)

miR-155 as a Biomarker in B-Cell Malignancies
por: Due, Hanne, et al.
Publicado: (2016)

Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor
por: Rodrigo-Domingo, Maria, et al.
Publicado: (2014)

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models
por: Falgreen, Steffen, et al.
Publicado: (2015)

Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma
por: Marcussen, Mette, et al.
Publicado: (2018)

Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives
por: Vesteghem, Charles, et al.
Publicado: (2019)

A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells
por: Kloster, Maria Bro, et al.
Publicado: (2012)

Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa
por: Marcussen, Mette, et al.
Publicado: (2017)

The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling
por: Berning, Philipp, et al.
Publicado: (2018)

Plerixafor
por: Slater, Susan
Publicado: (2012)

Proof of the Concept to Use a Malignant B Cell Line Drug Screen Strategy for Identification and Weight of Melphalan Resistance Genes in Multiple Myeloma
por: Bøgsted, Martin, et al.
Publicado: (2013)

Anti-Apoptotic Effects of Lentiviral Vector Transduction Promote Increased Rituximab Tolerance in Cancerous B-Cells
por: Ranjbar, Benyamin, et al.
Publicado: (2016)

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization
por: Jørgensen, Astrid S., et al.
Publicado: (2021)

Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates
por: Bilgrau, Anders E., et al.
Publicado: (2016)

Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man
por: Bergkvist, Kim Steve, et al.
Publicado: (2014)

Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma
por: Karstensen, Kasper Thystrup, et al.
Publicado: (2020)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience
por: Basak, Grzegorz Wladyslaw, et al.
Publicado: (2010)

A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma
por: Issa, Issa Ismail, et al.
Publicado: (2021)

The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by “on-demand” addition of plerixafor to granulocyte–colony-stimulating factor
por: Girbl, Tamara, et al.
Publicado: (2014)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis
por: Jespersen, Ditte Starberg, et al.
Publicado: (2019)

MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index
por: Due, Hanne, et al.
Publicado: (2020)

Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition
por: Sison, Edward Allan R., et al.
Publicado: (2014)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

MicroRNA‐9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4
por: Hersi, Hersi Mohamed, et al.
Publicado: (2018)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow
por: Devi, Sapna, et al.
Publicado: (2013)

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma
por: Thomsen, Emil Aagaard, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5nss5nvd9g48tr9op3fhdferps